SPS
TGTX icon

Susquehanna Portfolio Strategies’s TG Therapeutics TGTX Stock Holding History

Susquehanna Portfolio Strategies’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-228,304
Closed -$5.34M – 300
2024
Q3 		$5.34M Hold
228,304
– – 0.36% 80
2024
Q2 		$4.06M Hold
228,304
– – 0.17% 141
2024
Q1 		$3.47M Hold
228,304
– – 0.08% 259
2023
Q4 		$3.9M Buy
+228,304
New +$2.65M 0.07% 324

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Susquehanna Portfolio Strategies's TGTX Position: Q4 2024 in Review

Susquehanna Portfolio Strategies sold out of TG Therapeutics (TGTX) in Q4 2024, closing a stake of 228,304 shares — an estimated $5.34M sold.

Susquehanna Portfolio Strategies first reported a position in TGTX in Q4 2023 and held it in 4 quarters. The position peaked at $5.34M in Q3 2024. 331 funds tracked by Wall St. Rank hold TGTX as of Q4 2024.

  • Susquehanna Portfolio Strategies reported no remaining TG Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Susquehanna Portfolio Strategies sold 228,304 TG Therapeutics shares in Q4 2024, an estimated $5.34M.
  • Susquehanna Portfolio Strategies first reported a position in TG Therapeutics in Q4 2023 and held it in 4 quarters.
  • Susquehanna Portfolio Strategies's TG Therapeutics position peaked at $5.34M in Q3 2024.
  • 331 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2024.

Based on Susquehanna Portfolio Strategies's 13F filing for Q4 2024, filed 14 Feb 2025.